Synairgen to start trial of SNG001 in COVID-19
March 20, 2020
“Synairgen to start trial of SNG001 in COVID-19”
Respiratory drug discovery and development company Synairgen has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research Authority (HRA) to conduct a trial of SNG001 in COVID-19 patients to potentially assist with the global outbreak of the virus. SNG001 is an inhaled formulation of interferon-beta-1a.